In a huge breakthrough for Alzheimer’s sufferers, the first drug proven to slow progression of the disease has been approved in the US. our local city, as well as news from across Australia and the world.
US Approves Groundbreaking Drug to Slow Cognitive Decline
In a landmark decision, the US Food and Drug Administration (FDA) has granted full approval to Leqembi, a breakthrough drug designed to slow cognitive decline in patients with early-stage Alzheimer’s disease.
Leqembi, developed by Eisai and Biogen, is the first ever drug that has been proven to delay the progression of cognitive decline in individuals suffering from mild dementia and other symptoms caused by early Alzheimer’s disease. The drug, administered intravenously every two weeks, was approved after rigorous clinical trials and extensive research.
The approval of Leqembi could be a game-changer in the field of Alzheimer’s treatment. Up until now, existing medications could only manage the symptoms of the disease. Leqembi, however, targets the disease itself, slowing its progression and offering hope to patients and their families.
“This is a historic moment in Alzheimer’s treatment,” said an FDA spokesperson. “Leqembi has shown significant promise in slowing cognitive decline, offering a new lifeline for those living with this devastating disease.”
The drug works by targeting and reducing beta-amyloid, a protein that forms harmful clumps in the brains of Alzheimer’s patients. During an 18-month study, lecanemab, the active ingredient in Leqembi, slowed the rate of cognitive decline by 27%.
Despite its promise, the drug’s high cost – $26,500 per patient annually – has raised concerns about affordability and accessibility. The manufacturers and health insurance companies are reportedly in discussions to address these issues.
While the approval of Leqembi marks a significant milestone, experts caution that it’s not a cure for Alzheimer’s. However, it does represent a major step forward in managing the disease and improving the quality of life for patients.
As the medical community celebrates this groundbreaking development, the focus now shifts to monitoring the drug’s long-term effects and making it accessible to all those who stand to benefit from it. The journey to conquer Alzheimer’s continues, but with the approval of Leqembi, there is newfound hope on the horizon.
Albion News is a great place to find informative, up-to-date news articles. We provide a wide range of unique articles that offer an interesting perspective on current events from around the world and from various different sources. You can easily search for the topics that matter most to you and explore in-depth pieces that provide insight into the issues and important debates occurring today. Albion News helps you stay informed with carefully researched and credible stories!
